SCHEMBL30584995

SCHEMBL30584995

COc1ccc(-c2noc(N3CCN(C(=O)Nc4cccc(Cl)c4)CC3)n2)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 3/20 0.64
▸ KMT2A Q03164 3/20 0.64
▸ TUBB4A P04350 2/20 0.60
▸ TUBB P07437 2/20 0.60
▸ TUBA3C P0DPH7 2/20 0.60
▸ TUBA1B P68363 2/20 0.60
▸ TUBA4A P68366 2/20 0.60
▸ TUBB4B P68371 2/20 0.60
▸ TUBB3 Q13509 2/20 0.60
▸ TUBB2A Q13885 2/20 0.60
▸ TUBB8 Q3ZCM7 2/20 0.60
▸ TUBA3E Q6PEY2 2/20 0.60
▸ TUBA1A Q71U36 2/20 0.60
▸ TUBA1C Q9BQE3 2/20 0.60
▸ TUBB6 Q9BUF5 2/20 0.60
▸ TUBB2B Q9BVA1 2/20 0.60
▸ TUBB1 Q9H4B7 2/20 0.60
▸ MAPT P10636 7/20 0.59
▸ NPC1 O15118 2/20 0.59
▸ LMNA P02545 2/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30584898 0.89 MAPT (0.64) MEN1KMT2ATUBB4ATUBBTUBA3C
SCHEMBL26306614 0.89 MAPT (0.65) MEN1KMT2AMAPTNPC1LMNA
SCHEMBL25435931 0.84 MAPT (0.66) MEN1KMT2AMAPTNPC1LMNA
SCHEMBL31546426 0.82 MAPT (0.78) MEN1KMT2AMAPTNPC1LMNA
SCHEMBL31546336 0.81 MAPT (0.71) MEN1KMT2AMAPTNPC1LMNA
SCHEMBL31546316 0.78 MAPT (0.76) MEN1KMT2AMAPTNPC1LMNA
SCHEMBL31546459 0.76 MEN1 (0.86) MEN1KMT2AMAPTLMNATP53
SCHEMBL30584872 0.75 MAPT (0.71) MEN1KMT2AMAPTNPC1LMNA
SCHEMBL13234933 0.75 MAPT (0.76) KMT2AMAPTLMNAHTTTHRB
SCHEMBL30584994 0.74 MAPT (0.70) MEN1KMT2AMAPTNPC1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4463452-B1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER ANIMA BIOTECH INC (US) 2025-07-30 — — EP disclosed
US-12344600-B2 c-Myc mRNA translation modulators and uses thereof in the treatment of cancer ANIMA BIOTECH INC. (US) 2025-07-01 — — US disclosed
US-20250109128-A1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER ANIMA BIOTECH INC. (US) 2025-04-03 — — US disclosed
EP-4463452-A2 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER Anima Biotech Inc. (US) 2024-11-20 — — EP disclosed
WO-2023177700-A2 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER ANIMA BIOTECH INC. (US) 2023-09-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12344600-B2 c-Myc mRNA translation modulators and uses thereof in the treatment of cancer MYC, MYCBP, MYCBP2 MEN1 1569/4885KMT2A 1404/4885TUBB4A 1332/4885
US-20250109128-A1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER MYC, MYCBP, MYCBP2 MEN1 1569/4885KMT2A 1404/4885TUBB4A 1332/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback